Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1526 - Ibrutinib and acalabrutinib in the treatment of relapsed/refractory chronic lymphocytic leukemia: a real-world analysis from the Czech Chronic Lymphocytic Leukemia Patients Registry

    Primary Author / Presenter(s)

  • TA

    Tomas Arpas, MD

    Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital
    Brno, Czech Republic

    • Co-Author(s)

  • AP

    Anna Panovská, MD, PhD

    Assistant professor
    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Jihomoravsky kraj, Czech Republic

  • LP

    Lenka Polcerova

    Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • M

    Martin Špaček, MD, PhD

    Consultant in Hematology
    First Department of Internal Medicine - Hematology, General University Hospital, Prague, Czech Republic
    Praha, Hlavni mesto Praha, Czech Republic

  • TS

    Tereza Shokralla

    1st Department of Medicine - Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
    Praha, Hlavni mesto Praha, Czech Republic

  • MS

    Martin Simkovic, MD

    Consultant
    4th Department of Internal Medicine-Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University, Hradec Kralove, Czech Republic
    Hradec Kralove, Hlavni mesto Praha, Czech Republic

  • PV

    Pavel Vodárek, MD, PhD

    Consultant
    4th Department of Internal Medicine – Hematology, University Hospital and Charles University Faculty of Medicine in Hradec Králové
    Hradec Králové, Kralovehradecky kraj, Czech Republic

  • JM

    Jana Mihályová, MD

    physician
    Department of Hematooncology, University Hospital
    Ostrava, Czech Republic

  • JZ

    Jana Zuchnická, MD

    Department of Hematooncology, University Hospital, Ostrava, Czech Republic
    Ostrava, Czech Republic

  • DL

    Daniel Lysak, MD

    Department of Hematology and Oncology, Medical School and Teaching Hospital in Plzen, Charles University in Prague
    Plzeň, Czech Republic

  • LM

    Lekaa Mohammad, MD

    Department of Hematology and Oncology, Medical School and Teaching Hospital in Plzen, Charles University in Prague
    Plzeň, Czech Republic

  • HM

    Heidi Mocikova, MD, PhD

    University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Department of Haematology, Prague, Czech Republic
    Praha, Czech Republic

  • TP

    Tomas Papajik, MD

    Prof, MD., head of institution
    Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc
    Olomouc, Olomoucky kraj, Czech Republic

  • ZK

    Zuzana Kubová, MD

    physician
    Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc
    Olomouc, Olomoucky kraj, Czech Republic

  • MB

    Martin Brejcha, MD, PhD

    Department of Hematology, Hospital Agel, Nový Jičín, Czech Republic
    Nový Jičín, Czech Republic

  • AH

    Adriana Heindorfer

    Department of Haematology, Hospital Liberec, Liberec, Czech Republic
    Liberec, Liberecky kraj, Czech Republic

  • LS

    Lukas Stejskal

    Haematology/Tranfusiology Department, Silesian Hospital Opava, Opava, Czech Republic
    Opava, Moravskoslezsky kraj, Czech Republic

  • PH

    Poul Hynek, MD

    Department of Hematology and Transfusion Medicine, Hospital Pelhrimov
    Pelhřimov, Czech Republic

  • DB

    Denisa Bakesova

    Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • mB

    maria Bucikova

    Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • EO

    Eva Ondroušková, PhD

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • JM

    Jitka Malcikova, PhD

    1. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic and 2. Central European Institute of Technology (CEITEC), Masaryk University
    Brno, Czech Republic

  • SP

    Sarka Pavlova, PhD

    senior scientist
    1. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic and 2. Central European Institute of Technology (CEITEC), Masaryk University,
    Brno, Czech Republic

  • Michael Doubek, MD, PhD

    Department head
    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic